Нарушение Ритма И Проводимости У Больных Анкилозирующим И Псориатическим Спондилоартритом
Keywords:
ПсА, АС, Сердечно-сосудистые заболевания, периферического артрита, анкилозирующим спондилитом
Abstract
Сердечно-сосудистые заболевания являются основной причиной смерти больных с анкилозирующим спондилитом (АС) и псориатическим артритом (ПсА) [1-4]. Показатели сердечно-сосудистой заболеваемости и смертности при АС и ПсА многократно превосходят популяционные значения, поэтому были разработаны Европейские рекомендации по особенностям наблюдения, лечения и оценки сердечно-сосудистого риска у больных спондилоартритами [1-5]. В указанных рекомендациях отмечено, что многие вопросы, касающиеся патологии сердечно-сосудистой системы при спондилоартритах, нуждаются в дальнейшей разработке.
References
1. Folomeeva O. M., Galushko E. A., Erdes S. F. Rasprostranennost' revmaticheskich zabolevaniy v populyaziyach vzroslogo naseleniya Rossii i SShA [The prevalence of rheumatic diseases in populations of the adult population of Russia and the United States]. Nauch-prakt. revmatologiya, 2008, no. 4, s. 4-13. (in Russian)
2. Han C., Robinson D. W., Hackett M. V., Paramore L. C., Fraeman K. H., Bala M. V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol, 2006, vol. 33, no. 11, pp. 2167-2172.
3. Haroon N. N., Paterson J. M., Li P., Inman R. D., Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population- based study. Ann intern Med, 2015, vol. 163, no. 6, pp. 409-416.
4. Rebrov A. P., Gaydukova I. Z., Poddubnyy D. A. Kardiovaskulyarnaya patologiya u bol'nych ankiloziruyuschim spondilitom [Cardiovascular disease in patients with ankylosing spondylitis]. Scientific and practical rheumatology, 2012, no. 2, pp. 100-105. (in Russian)
5. Heslinga S. C., Van den Oever I. A., Van Sijl A. M., Peters M. J., Van der Horst-Bruinsma I.E., Smulders Y. M., Nurmohamed M. T. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord, 2015, vol. 9, no. 16, pp. 80.
6. Ozkan Y. Cardiac Involvement in Ankylosing Spondylitis. J Clin Med Res, 2016, vol. 8, no. 6, pp. 427-430. doi: 10.14740/jocmr2488w
7. Klingberg E., Svealv B. G., Tang M. S., Bech-Hanssen O., Forsblad-d'Elia H., Bergfeldt L. Aortic Regurgitation Is Common in Ankylosing Spondylitis: Time for Routine Echocardiography Evaluation? Am J Med, 2015, vol. 128, no. 11, pp. 1244-1250.e1. doi: 10.1016/j.amjmed.2015.04.032
8. Bergfeldt L., Edhag O., Vedin L., Vallin H. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker- treated men. Ami J Med, 1982, vol. 73, no. 2, pp.187-191
9. Bergfeldt L. HLA B27-associated rheumatic diseases with severe cardiac bradyarrhythmias. Clinical features and prevalence in 223 men with permanent pacemakers. Am J Med, 1983, vol. 75, no. 2, pp. 210-215.
10. Bergfeldt L., Vallin H., Edhag O. Complete heart block in HLA B27 associated disease. Electrophysiological and clinical characteristics. Br Heart J, 1984, vol. 51, no. 2, pp. 184-188.
11. Münzel, T., Sinning, C., Post, F., Warnholtz, A., Schulz, E., Mu¨nzel, T., & Mu¨nzel, M. (2009). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. https://doi.org/10.1080/07853890701854702.
12. Sanchez-Piedra, C., Diaz-Torne, C., Manero, J., Pego-Reigosa, J. M., Rúa-Figueroa, Í., Gonzalez-Gay, M. A., Gomez-Reino, J., & Alvaro-Gracia, J. M. (2020). Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases, 79(7), 988–990. https://doi.org/10.1136/annrheumdis-2020-217948.
13. D’Antiga, L. (2020). Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transplantation, 26(6), 832–834. https://doi.org/10.1002/lt.25756
14. Uhrin, Z., Kuzis, S., & Ward, M. M. (n.d.). Exercise and Changes in Health Status in Patients With Ankylosing Spondylitis. Retrieved August 22, 2021, from https://jamanetwork.com/
15. Steyers, C. M., & Miller, F. J. (2014). Endothelial Dysfunction in Chronic Inflammatory Diseases. Int. J. Mol. Sci, 15, 11324–11349. https://doi.org/10.3390/ijms150711324
16. Liew, J. W., Castillo, M., Zaccagnino, E., Katz, P., Haroon, N., & Gensler, L. S. (2020). Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic. 2(9), 533–539. https://doi.org/10.1002/acr2.11174
17. Roux, C. H., Brocq, O., Gerald, F., Pradier, C., & Bailly, L. (2020). Clinical impact of COVID-19 on a French population of spondyloarthritis patients. In Clinical Rheumatology (Vol. 39, Issue 11, pp. 3185–3187). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s10067-020-05413-9
18. Vasina, L. V., Petrishchev, N. N., & Vlasov, T. D. (2017). Markers of endothelial dysfunction. Regional Blood Circulation and Microcirculation, 16(1), 4–15. https://doi.org/10.24884/1682-6655-2017-16-1-4-15
19. Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2021). COVID-19 and the clinical course of rheumatic manifestations. Clinical Rheumatology, 40(7), 2611–2619. https://doi.org/10.1007/s10067-021-05691-x
20. Sari, I., Okan, T., Akar, S., Cece, H., Altay, C., Secil, M., Birlik, M., Onen, F., & Akkoc, N. (2006). Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology, 45(3), 283–286. https://doi.org/10.1093/RHEUMATOLOGY/KEI145
21. Abdurakhmanova N. M., Akhmedov K. S. Clinical features of ankylosing spondilitis in postcovidal period. – 2021.
22. M Rakhimova, K Akhmedov, M Tagaeva, S Sadikova Endothelin-1biomarker Features In Patients With Ankylosing Spondylitis After COVID-19 … - Journal of Positive School Psychology, 2022
23. Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection MB Rakhimova, KS Akhmedov, YA Turaev - ACADEMICIA: An International Multidisciplinary …, 2021
24. THE IMPACT OF SEQUELAE OF COVID-19 ON THE COURSE OF ANKYLOSING SPONDYLITIS MB Rakhimova, KS Akhmedov - Central Asian journal of medicine, 2021
2. Han C., Robinson D. W., Hackett M. V., Paramore L. C., Fraeman K. H., Bala M. V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol, 2006, vol. 33, no. 11, pp. 2167-2172.
3. Haroon N. N., Paterson J. M., Li P., Inman R. D., Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population- based study. Ann intern Med, 2015, vol. 163, no. 6, pp. 409-416.
4. Rebrov A. P., Gaydukova I. Z., Poddubnyy D. A. Kardiovaskulyarnaya patologiya u bol'nych ankiloziruyuschim spondilitom [Cardiovascular disease in patients with ankylosing spondylitis]. Scientific and practical rheumatology, 2012, no. 2, pp. 100-105. (in Russian)
5. Heslinga S. C., Van den Oever I. A., Van Sijl A. M., Peters M. J., Van der Horst-Bruinsma I.E., Smulders Y. M., Nurmohamed M. T. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord, 2015, vol. 9, no. 16, pp. 80.
6. Ozkan Y. Cardiac Involvement in Ankylosing Spondylitis. J Clin Med Res, 2016, vol. 8, no. 6, pp. 427-430. doi: 10.14740/jocmr2488w
7. Klingberg E., Svealv B. G., Tang M. S., Bech-Hanssen O., Forsblad-d'Elia H., Bergfeldt L. Aortic Regurgitation Is Common in Ankylosing Spondylitis: Time for Routine Echocardiography Evaluation? Am J Med, 2015, vol. 128, no. 11, pp. 1244-1250.e1. doi: 10.1016/j.amjmed.2015.04.032
8. Bergfeldt L., Edhag O., Vedin L., Vallin H. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker- treated men. Ami J Med, 1982, vol. 73, no. 2, pp.187-191
9. Bergfeldt L. HLA B27-associated rheumatic diseases with severe cardiac bradyarrhythmias. Clinical features and prevalence in 223 men with permanent pacemakers. Am J Med, 1983, vol. 75, no. 2, pp. 210-215.
10. Bergfeldt L., Vallin H., Edhag O. Complete heart block in HLA B27 associated disease. Electrophysiological and clinical characteristics. Br Heart J, 1984, vol. 51, no. 2, pp. 184-188.
11. Münzel, T., Sinning, C., Post, F., Warnholtz, A., Schulz, E., Mu¨nzel, T., & Mu¨nzel, M. (2009). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. https://doi.org/10.1080/07853890701854702.
12. Sanchez-Piedra, C., Diaz-Torne, C., Manero, J., Pego-Reigosa, J. M., Rúa-Figueroa, Í., Gonzalez-Gay, M. A., Gomez-Reino, J., & Alvaro-Gracia, J. M. (2020). Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases, 79(7), 988–990. https://doi.org/10.1136/annrheumdis-2020-217948.
13. D’Antiga, L. (2020). Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transplantation, 26(6), 832–834. https://doi.org/10.1002/lt.25756
14. Uhrin, Z., Kuzis, S., & Ward, M. M. (n.d.). Exercise and Changes in Health Status in Patients With Ankylosing Spondylitis. Retrieved August 22, 2021, from https://jamanetwork.com/
15. Steyers, C. M., & Miller, F. J. (2014). Endothelial Dysfunction in Chronic Inflammatory Diseases. Int. J. Mol. Sci, 15, 11324–11349. https://doi.org/10.3390/ijms150711324
16. Liew, J. W., Castillo, M., Zaccagnino, E., Katz, P., Haroon, N., & Gensler, L. S. (2020). Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic. 2(9), 533–539. https://doi.org/10.1002/acr2.11174
17. Roux, C. H., Brocq, O., Gerald, F., Pradier, C., & Bailly, L. (2020). Clinical impact of COVID-19 on a French population of spondyloarthritis patients. In Clinical Rheumatology (Vol. 39, Issue 11, pp. 3185–3187). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s10067-020-05413-9
18. Vasina, L. V., Petrishchev, N. N., & Vlasov, T. D. (2017). Markers of endothelial dysfunction. Regional Blood Circulation and Microcirculation, 16(1), 4–15. https://doi.org/10.24884/1682-6655-2017-16-1-4-15
19. Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2021). COVID-19 and the clinical course of rheumatic manifestations. Clinical Rheumatology, 40(7), 2611–2619. https://doi.org/10.1007/s10067-021-05691-x
20. Sari, I., Okan, T., Akar, S., Cece, H., Altay, C., Secil, M., Birlik, M., Onen, F., & Akkoc, N. (2006). Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology, 45(3), 283–286. https://doi.org/10.1093/RHEUMATOLOGY/KEI145
21. Abdurakhmanova N. M., Akhmedov K. S. Clinical features of ankylosing spondilitis in postcovidal period. – 2021.
22. M Rakhimova, K Akhmedov, M Tagaeva, S Sadikova Endothelin-1biomarker Features In Patients With Ankylosing Spondylitis After COVID-19 … - Journal of Positive School Psychology, 2022
23. Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection MB Rakhimova, KS Akhmedov, YA Turaev - ACADEMICIA: An International Multidisciplinary …, 2021
24. THE IMPACT OF SEQUELAE OF COVID-19 ON THE COURSE OF ANKYLOSING SPONDYLITIS MB Rakhimova, KS Akhmedov - Central Asian journal of medicine, 2021
Published
2023-07-04
How to Cite
Рахимова Мадина Боходировна. (2023). Нарушение Ритма И Проводимости У Больных Анкилозирующим И Псориатическим Спондилоартритом. Central Asian Journal of Medical and Natural Science, 4(4), 17-25. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1656
Section
Articles
